294182-06-2

Basic information

• Product Name: 2-(5-bromopyridin-2-yl)-1-(2,4-difluorophenyl)-2,2-difluoroethanone
• Synonyms: 2-(5-bromopyridin-2-yl)-1-(2,4-difluorophenyl)-2,2-difluoroethanone
• CAS NO: 294182-06-2
• Molecular Weight: 348.094
• Mol File: 294182-06-2.mol
• Article Data: 22

Chemical Properties

• CAS DataBase Reference: 2-(5-bromopyridin-2-yl)-1-(2,4-difluorophenyl)-2,2-difluoroethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(5-bromopyridin-2-yl)-1-(2,4-difluorophenyl)-2,2-difluoroethanone(294182-06-2)
• EPA Substance Registry System: 2-(5-bromopyridin-2-yl)-1-(2,4-difluorophenyl)-2,2-difluoroethanone(294182-06-2)

Safety Data

• Hazardous Substances Data: 294182-06-2(Hazardous Substances Data)

Usage

General Description

2-(5-bromopyridin-2-yl)-1-(2,4-difluorophenyl)-2,2-difluoroethanone is a chemical compound with the molecular formula C13H7BrF4N2O. It is a yellow solid with a molecular weight of 362.11 g/mol. 2-(5-bromopyridin-2-yl)-1-(2,4-difluorophenyl)-2,2-difluoroethanone is a ketone derivative that contains bromine, fluorine, and nitrogen atoms in its structure. It may be used as a building block in the synthesis of other organic compounds or as a reagent in chemical reactions. It is important to handle this compound with caution and use appropriate safety measures, as it may be hazardous if not handled properly.

Upstream product

• 348-57-2 2,4-difluorobromobenzene 
• 294181-95-6 2-(5-bromopyridine-2-yl)-2,2-difluoroacetic acid ethyl ester 
• 624-28-2 2,5-dibromopyridine 
• 144025-04-7 (2,4-difluorophenyl)magnesium bromide 

Relevant articles and documents

Fungal lanosterol 14α-demethylase (CYP51) inhibitor Treatment of recurrent vulvovaginal candidiasis Treatment of onychomycosis

Developing a rationally designed, more selective azole antifungal agent that specifically targets the fungal CYP51 over the host CYP51 is a severe unmet need considering a massive shortfall in novel antifungal agents. In this context, oteseconazole (VT-1161) represents a very exciting new development targeting serious fungal infections caused by a wide variety of fungal pathogens including multidrug-resistant Candida responsible for recurrent vulvovaginal candidiasis. This monograph details the various in vitro and in vivo properties exhibited by oteseconazole as well as its current status in clinical trials.

METALLOENZYME INHIBITOR COMPOUNDS

The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

ANTIFUNGAL COMPOUND PROCESS

The present invention relates to a process for preparing compound 1 that is useful as an antifungal agent. In particular, the invention seeks to provide new methodology for preparing compound 1 and substituted derivatives thereof.